Existing drug treatments cannot significantly shorten the clinical cure time of children with COVID-19

Authors

  • Mengting Li Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Yang Wang Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Hua Xu Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Changlin Liu Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Liang Shi Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Qi Ye Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Jun Wang Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Sichan Li Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Yan Mei Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Liuliu Gao Department of Clinical Pharmacy, Wuhan Children’s Hospital (Wuhan Meternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

DOI:

https://doi.org/10.3855/jidc.13491

Keywords:

Coronavirus disease 2019, pediatric patients;, different treatment agents;, cure rate

Abstract

Introduction: COVID-19 has become a global health security issue, it has caused more than half a million deaths worldwide so far, the treatment strategies are the most concerned issues for clinicians. In this study, the treatments and outcomes in 40 pediatric patients diagnosed with COVID-19 and treated with different drugs were evaluated.

Methodology: All cases were diagnosed with COVID-19 nucleic acid positive by using RT-PCR or clinical manifestations, imaging specific characteristics and epidemiological clinical diagnosis. The biological information and first symptom of all cases were collect. A variety of treatments were employed and the outcomes were evaluated by Cox regression analysis. Multivariable analysis was performed to evaluate cure rate at 14 days with different drug treatment.

Results: The average length of hospital stay was 10.4 days. The cure rate was increased with the treatment time extended and 90% of pediatric patients were cured and discharged after 14 days’ treatment. And multivariable analysis results proved that none of the covariates were related to the cure rate at 14 days with different drug treatment since p values were over 0.05.

Conclusions: Multivariable analysis suggested that the present drug treatments cannot significantly shorten the clinical cure time and improve the cure rate of children with COVID-19.

Downloads

Published

2020-09-30

How to Cite

1.
Li M, Wang Y, Xu H, Liu C, Shi L, Ye Q, Wang J, Li S, Mei Y, Gao L (2020) Existing drug treatments cannot significantly shorten the clinical cure time of children with COVID-19. J Infect Dev Ctries 14:963–967. doi: 10.3855/jidc.13491

Issue

Vol. 14 No. 09: September 2020

Section

Coronavirus Pandemic

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC